IGCIGC Pharma, Inc.

NYSE igcpharma.com


$ 0.44 $ 0.00 (0.95 %)    

Thursday, 27-Jun-2024 11:32:44 EDT
QQQ $ 482.07 $ 1.24 (0.26 %)
DIA $ 391.62 $ 0.32 (0.08 %)
SPY $ 546.37 $ 0.86 (0.16 %)
TLT $ 93.57 $ 0.37 (0.4 %)
GLD $ 215.08 $ 2.41 (1.13 %)
$ 0.425
$ 0.44
$ 0.00 x 0
$ 0.00 x 0
$ 0.44 - $ 0.44
$ 0.25 - $ 0.91
84,228
na
32.15M
$ 1.63
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 06-24-2024 03-31-2024 10-K
2 02-14-2024 12-31-2023 10-Q
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 07-07-2023 03-31-2023 10-K
6 02-14-2023 12-31-2022 10-Q
7 11-01-2022 09-30-2022 10-Q
8 08-05-2022 06-30-2022 10-Q
9 06-22-2022 03-31-2022 10-K
10 02-10-2022 12-31-2021 10-Q
11 10-29-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 06-14-2021 03-31-2021 10-K
14 02-16-2021 12-31-2020 10-Q
15 11-20-2020 09-30-2020 10-Q
16 08-19-2020 06-30-2020 10-Q
17 07-13-2020 03-31-2020 10-K
18 02-10-2020 12-31-2019 10-Q
19 11-06-2019 09-30-2019 10-Q
20 08-09-2019 06-30-2019 10-Q
21 06-14-2019 03-31-2019 10-K
22 02-12-2019 12-31-2018 10-Q
23 10-16-2018 09-30-2018 10-Q
24 08-03-2018 06-30-2018 10-Q
25 06-21-2018 03-31-2018 10-K
26 02-20-2018 12-31-2017 10-Q
27 11-17-2017 09-30-2017 10-Q
28 08-18-2017 06-30-2017 10-Q
29 07-14-2017 03-31-2017 10-K
30 02-21-2017 12-31-2016 10-Q
31 11-21-2016 09-30-2016 10-Q
32 08-16-2016 06-30-2016 10-Q
33 07-14-2016 03-31-2016 10-K
34 02-16-2016 12-31-2015 10-Q
35 11-13-2015 09-30-2015 10-Q
36 08-14-2015 06-30-2015 10-Q
37 07-14-2015 03-31-2015 10-K
38 02-12-2015 12-31-2014 10-Q
39 11-13-2014 09-30-2014 10-Q
40 08-14-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 igc-pharma-q4-2024-gaap-eps-004-sales-295000k-beat-193000k-estimate

IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.04) per share. The company reported quarterly sales of $295.000 thousan...

 ascendiant-capital-reiterates-buy-on-igc-pharma-maintains-325-price-target

Ascendiant Capital analyst Edward Woo reiterates IGC Pharma (AMEX:IGC) with a Buy and maintains $3.25 price target.

 igc-pharma-publishes-study-in-european-society-of-medicine-for-impact-of-cyp2c9-genetic-polymorphism-on-pharmacokinetics-of-delta-9-tetrahydrocannabinol

-- Study Deepens Understanding of Treatments for Alzheimer's Patients, Enabling More Effective Treatments --

Core News & Articles

https://subscriber.politicopro.com/article/2024/05/justice-department-poised-to-post-plans-for-marijuana-reclassification-00158...

Core News & Articles

https://www.marijuanamoment.net/dea-appears-to-question-marijuanas-medical-value-despite-rescheduling-recommendation/ 

Core News & Articles

https://twitter.com/KevinSabet/status/1787569052782846142 

Core News & Articles

https://www.marijuanamoment.net/florida-gop-formally-opposes-marijuana-legalization-ballot-initiative-clearing-path-for-desanti...

Core News & Articles

https://www.wsj.com/finance/regulation/declassifying-cannabis-still-leaves-pot-stocks-in-limbo-26d417ec

Core News & Articles

https://www.marijuanamoment.net/schumer-says-dea-marijuana-rescheduling-decision-is-historic-but-he-remains-strongly-committed-...

 igc-pharma-announces-interim-results-for-igc-ad1-in-reducing-alzheimers-agitation-results-indicate-that-igc-ad1-clinically-reduced-agitation-compared-to-placebo

-Reuters

Core News & Articles

https://www.audacy.com/talk1370/news/business/cannabis-seizures-at-checkpoints-by-us-mexico-border-frustrates-state-authorized-...